Belinostat was FDA-approved in July 2014 for relapsed or refractory (R/R) PTCL, showing pan-inhibitory effects on HDAC proteins.179 Common adverse effects of belinostat include nausea, vomiting, diarrhea, dysgeusia, fatigue, and severe hematologic treatment-related adverse events.180,181 Further, dosing considerations are needed for patients with hepatic impairment due to liver metabolism.182 Belinostat is being explored for other myeloid malignancies and solid tumors, including glioblastoma and small-cell lung cancer.183–186. The gene discussed is HDAC9; the disease is mature T-cell and NK-cell non-Hodgkin lymphoma.